• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Pacira BioSciences Inc.

    4/21/25 4:00:18 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Pacira BioSciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    695127100

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    695127100


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    345,625.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    345,625.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    345,625.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    695127100


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    345,625.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    345,625.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    345,625.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    695127100


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    345,625.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    345,625.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    345,625.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pacira BioSciences, Inc.
    (b)Address of issuer's principal executive offices:

    2000 Sierra Point Parkway, Suite 900, Brisbane,California 94005
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    695127100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:04/17/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:04/17/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:04/17/2025
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of April 17, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $PCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    12/9/2025$27.00Equal Weight
    Barclays
    11/17/2025Buy
    H.C. Wainwright
    7/25/2025$30.00Hold → Buy
    Truist
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pacira BioSciences with a new price target

    Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00

    12/9/25 8:52:11 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pacira BioSciences

    H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy

    11/17/25 9:41:22 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences upgraded by Truist with a new price target

    Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00

    7/25/25 8:53:01 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President, Finance Riker Lauren covered exercise/tax liability with 2,751 shares and sold $83,240 worth of shares (4,000 units at $20.81), decreasing direct ownership by 11% to 52,313 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Administrative Officer Williams Kristen covered exercise/tax liability with 17,134 shares and sold $269,703 worth of shares (13,137 units at $20.53), decreasing direct ownership by 19% to 131,303 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:01 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Teehan Brendan covered exercise/tax liability with 5,182 shares, decreasing direct ownership by 10% to 49,220 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:23:46 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction ("NOPAIN") Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation's leading nonpartisan coalition dedicated to ensuring patient access to non-addictive pain management approaches Data were gathered from a national awareness, trial, and usage (ATU) survey of nearly 750 hospitals, he

    2/12/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Four employees received stock options to purchas

    2/9/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

    -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ

    1/28/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    SEC Filings

    View All

    SEC Form 144 filed by Pacira BioSciences Inc.

    144 - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/2/26 10:55:35 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

    1/28/26 8:01:57 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

    1/8/26 4:02:31 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:55 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:46 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/14/24 4:35:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    View All

    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

    -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ

    1/28/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

    -- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin

    1/13/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

    --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. "Despite its prevalence, there c

    12/18/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Financials

    Live finance-specific insights

    View All

    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

    -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha

    11/6/25 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

    BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the co

    10/30/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Second Quarter 2025 Financial Results

    -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Total revenues of $181.1 millionNet product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°Net loss of $4.8 million, or $0.11 per share (basic and di

    8/5/25 4:00:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/19/24 2:40:54 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/14/23 1:31:32 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/23/23 3:52:35 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care